Pharma Focus Asia

Eisai and Ewopharma Announce Commercial Partnership

Friday, June 23, 2017

Ewopharma, a pharmaceutical marketing company and Eisai Co., Ltd. (TYO: 4523), a leading global research and development-based pharmaceutical company are pleased to announce that as of 1st April 2017 Ewopharma acquired the rights to commercialise several of Eisai's products in eleven countries in Central and Eastern Europe (CEE).

Ewopharma will commercialise Halaven® (eribulin mesylate) in nine countries within the European Union (EU) (Bulgaria, Croatia, Estonia, Hungary, Latvia, Lithuania, Poland, Romania and Slovenia) and in two countries outside of the EU (Bosnia & Herzegovina and Serbia). Ewopharma will also commercialise Targretin® (bexarotene) in Hungary and Poland as well as Zonegran® (zonisamide) in Hungary.

Ewopharma will be responsible for all aspects of pricing, reimbursement, marketing and distribution. Eisai will supply product and also provide significant product training and support across the relevant brands.

"Eisai is a R&D based pharmaceutical company with a global focus on Neurology and Oncology", said Gary Hendler, Chairman & CEO Eisai EMEA. "We are committed to discovering and developing innovative medicines for patients in therapeutic areas of high unmet medical needs and our partnership with Ewopharma will help to provide further access for patients who desperately need new treatment options."

"Eisai is a reputed established organisation with a product portfolio that matches our corporate development strategy and our intention to bring new, innovative treatments to Central Eastern Europe," adds Reto Schaberl, Head of Business Development, Ewopharma AG. "Eisai's outlook on long-term, sustainable commercial partnerships matches our own culture. We are therefore extremely pleased to be able to partner with Eisai and help expand access to Halaven, Targretin and Zonegran. We look forward to an exciting, fruitful collaboration."

This partnership is an example of Eisai's commitment to novel collaborative working practices and underscores Eisai's human health care mission, the company's commitment to innovative solutions in disease prevention, cure and care for the health and well-being of people worldwide.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024ISPE Singapore Affiliate Conference & Exhibition 2024Rehab Expo 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024